Merrill Goozner
A new study designed to expand the use of Amgen Inc.'s erythropoiesis-stimulating agents (ESAs) in patients with early stage...
The Slow Death of a Blockbuster
Bad news continues to mount for erythropoiesis-stimulating agents (ESAs), the flagship products of the biotechnology industry. Far from developing new markets, postmarket clinical trials by Amgen and J&J continue to point towards a much smaller appropriate patient population for Aranesp and Procrit.